Peps
What is Peptide YY?
Peptide YY is a gut-hormone family involved in feeding regulation. The selected trial studied PYY3-36 alone and with GLP-1; the combined result should not be described as a proven PYY-alone effect.
Biological role or research focus
Acute appetite signaling.
An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss.
Role reference: Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. · 2014 ↗
Names you may encounter
PYY · PYY3-36 · PYY 3-36
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Gut hormone family; PYY forms must be distinguished
- Research focus
- Acute appetite signaling
- Featured evidence
- Human randomized crossover study
- Source check
- October 4, 2026
Biology & proposed mechanism
The study evaluated whether two gut-hormone signals interact in controlling acute intake. PYY1-36 and PYY3-36 are distinct forms with different receptor contexts.
Research context & identity
This profile concerns short-term infusion physiology in overweight men, rather than a demonstrated chronic weight-management treatment.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized crossover study · 2014
PYY3-36 with and without GLP-1
What did this publication test, and what did it find?
- Population / model
- 25 overweight healthy men.
- Study design
- Randomized double-blind four-condition crossover comparing PYY3-36, GLP-1, their combination, and placebo.
- Main finding
- Neither individual infusion significantly reduced food intake in this experiment. The combination reduced intake by 30.4%; nausea increased slightly.
- Limits & context
- An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Peptide YY. ↗
Current opinion in endocrinology, diabetes, and obesity · 2008 Feb · Evaluation Study, Journal Article, Review
Peptide YY: A Paneth cell antimicrobial peptide that maintains Candida gut commensalism. ↗
Science (New York, N.Y.) · 2023 Aug 4 · Journal Article
Read available full text ↗
Virilizing insulinoma. ↗
Endokrynologia Polska · 2025 · Journal Article, Case Reports
Bariatric Surgery: It's Not Just Incretins! ↗
The Journal of clinical endocrinology and metabolism · 2022 Jan 18 · Editorial, Research Support, N.I.H., Extramural, Comment
Read available full text ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
Nausea and route-specific tolerability matter. A brief controlled infusion cannot establish chronic safety.
Evidence boundaries
An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Did PYY3-36 alone significantly reduce intake in this trial?
- What material, population, and route were actually studied?
- An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did PYY3-36 alone significantly reduce intake in this trial?
No. The significant intake reduction was observed with the combination, not either individual infusion.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.